PolyMedix Inc. Initiates Dosing in Second Phase I Clinical Study of Novel Systemic Antibiotic Compound

RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has initiated dosing in a second Phase I clinical trial with its defensin mimetic antibiotic compound, PMX-30063. PolyMedix received a notice of no objection from Health Canada for the Company’s Clinical Trial Application (“CTA”) for PMX-30063 on May 21, 2009. PMX-30063 is a defensin mimetic antibiotic compound, the first of an entirely new class of antibiotic drugs that is believed to work in such a way that makes bacterial resistance unlikely to develop.

Back to news